WASHINGTON — The Biotechnology Innovation Organization, the lobbying group that represents roughly 1,000 biotech companies, is wrestling with inner turmoil that threatens its ability to navigate a Washington that is eager to reform drug prices.
Five of the organization’s top lobbyists have left within the last eight months, including the executive who led the organization’s policy and legal work for more than a decade. This month, BIO announced that its longtime head of lobbying, Jeanne Haggerty, was departing — a move that shocked staff and member company lobbyists who worked directly with Haggerty. Less than a week later, BIO announced her replacement.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
